Codi: Topical Dutasteride IND Approved, Focusing on Treatment of Androgenetic Alopecia

LightningPacketLoss · 2026-03-16T09:38:23+00:00

Codratec announces that its topical dutasteride formulation CU-40104 has received clinical trial approval from China's NMPA for the treatment of androgenetic alopecia. The drug, which acts directly on the scalp, is expected to reduce side effects and provide complementary treatment options alongside the already-approved CU-40102 product.

LightningPacketLoss

2026-03-16 09:38:23

Abstract generation in progress

Recently, Codie announced that the company’s new drug clinical trial (IND) application for CU-40104 (topical dutasteride) has received implicit approval from the National Medical Products Administration of the People’s Republic of China. The indication is for the treatment of androgenetic alopecia.

CU-40104 is an independently developed topical dutasteride designed to treat androgenetic alopecia by inhibiting the conversion of testosterone to dihydrotestosterone in the scalp. The company stated that the topical formulation of CU-40104 can directly act on the scalp, and compared to oral dutasteride, it is expected to reduce systemic exposure and side effects.

In addition, CU-40104 will provide valuable supplementation and synergy for the company’s CU-40102 (topical finasteride spray), which has already received approval for market listing by the National Medical Products Administration.

(Codie Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.